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Introduction: We aimed to evaluate the safety and efficacy of
canfosfamide in combination with carboplatin and paclitaxel as
first-line therapy in patients with locally advanced or metastatic
non-small cell lung cancer.
Methods: This was a phase 1-2a, multicenter, dose-ranging trial that
enrolled patients with stage IIIB or IV non-small cell lung cancer
with measurable disease. Patients received canfosfamide in doses
ranging from 400 to 1000 mg/m2 intravenously (IV) with carbopla-
tin at area under the curve 6 IV and paclitaxel at 200 mg/m2 IV day
1 every 3 weeks. The primary end point was objective response rate,
and the secondary endpoints were safety and progression-free sur-
vival.
Results: One hundred twenty-nine patients were treated with can-
fosfamide at dose levels of 400 (n 3), 500 (n 51), 750 (n 54),
and 1000 mg/m2 (n  21). Objective tumor responses by RECIST
were observed in 40 patients [34% (95% confidence interval [CI],
26–44)], the median progression-free survival was 4.3 months (95%
CI, 3.7–5.2) and the median survival 9.9 months (95% CI, 7.7–11.9).
The percent of patients alive at 1 year was 43.1%. The overall safety
profile of the combination was acceptable and consistent with the
profiles of the individual agents. In an exploratory analysis, patients
receiving the optional maintenance canfosfamide therapy had a
prolonged median survival of 16.8 months compared with those
eligible for but not receiving maintenance therapy at 8.8 months
(hazard ratio  0.38, p  0.001).
Conclusions: The combination of canfosfamide with carboplatin
and paclitaxel chemotherapy is well tolerated and active. Mainte-
nance canfosfamide may further improve outcomes. This regimen is
worthy of additional study.
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Non-small cell lung cancer (NSCLC) is the leading causeof cancer-related death in both men and women in the
US and most patients have inoperable disease at the time of
diagnosis.1 First-line treatment of advanced NSCLC primar-
ily consists of platinum-based chemotherapy regimens that
are only moderately effective, prolonging median survival by
a few months.2–4 Hence, novel strategies to improve response
to treatment and duration of response are needed.
The glutathione S-transferases (GSTs) are a family of
ubiquitously expressed intracellular enzymes that facilitate
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the conjugation of toxic compounds with the antioxidant
glutathione, leading to excretion of the toxins.5 The GST
enzymes, in particular the Pi isoform glutathione S-trans-
ferase P1–1 (GST P1–1), are widely overexpressed in cancer
cells, including NSCLC.6,7 Overexpression of GST P1–1 is
correlated with poor prognosis and chemotherapy resistance,
including resistance to platinum agents and taxanes, which
are not direct substrates of the GST pathway.5,8,9 Recently,
GST P1–1 has been shown to play a role in regulating kinase
signaling in the stress response, apoptosis, and proliferation
pathways, suggesting that the influence of GST P1–1 activity
on vital cellular functions is pervasive.10
Canfosfamide HCl (TELCYTA, TLK286) is a novel
glutathione analog phosphorodiamidate prodrug that is acti-
vated in cancer cells by GST P1–1.11 The active metabolites
of canfosfamide are believed to be cytotoxic, and they exhibit
their toxicity by means of two distinct mechanisms. First,
they directly induce stress response pathway-mediated cellu-
lar apoptosis through the mitogen-activated protein kinase
signaling protein MKK4. Second, the cleaved moiety of the
prodrug remains in the GST P1–1 binding pocket, impairing
GST P1–1-mediated chemotherapy resistance.12–15 Canfosf-
amide has been shown to be active against many cancer
types, including NSCLC, both as a single agent and in
combination with chemotherapy.13,16,17 In vitro data have
demonstrated that combinations of canfosfamide with plati-
nums and taxanes are synergistic in A549 human lung cancer
cells.18 We performed a multicenter, phase 1-2a, dose-rang-
ing clinical trial to determine the safety and efficacy of
canfosfamide in combination with carboplatin and paclitaxel
as first-line therapy for advanced NSCLC.
METHODS
Patients
Eligibility criteria included a confirmed histologic di-
agnosis of NSCLC, clinical stage IIIB (with malignant pleu-
ral effusion) or IV. No previous chemotherapy for advanced
disease was allowed, although one previous adjuvant or
neo-adjuvant regimen was permitted. Measurable disease by
RECIST and Eastern Cooperative Oncology Group perfor-
mance status of 0 or 1 was required.19,20 Patients had to have
adequate hematologic, renal, and hepatic function. Known
central nervous system (CNS) metastases were excluded
unless the patient had undergone definitive therapy and was
neurologically stable without chronic steroid or anticonvul-
sant therapy.
Study Design
The trial was designed as a dose-ranging phase 1 study
with the primary aim of determining the maximum tolerated
dose (MTD) and safety profile of canfosfamide in combina-
tion with carboplatin and paclitaxel chemotherapy, to be
followed by a phase 2 study with the primary aim of estimat-
ing the objective response rate (ORR) of canfosfamide in
combination with carboplatin and paclitaxel. The secondary
objectives included estimating the progression-free survival
(PFS), overall survival (OS), and disease control rate. The
study protocol was approved and monitored by each local
institutional review board, and all patients provided written
informed consent (clinicaltrials.gov number NCT00088556).
The study was sponsored by Telik, Inc.
Treatment and Assessments
All patients were treated with canfosfamide, carbopla-
tin at area under the curve 6 and paclitaxel at 200 mg/m2
intravenous every 21 days in 3-week cycles to a maximum of
six cycles of combination therapy until progressive disease or
unacceptable toxicity. At the completion of combination
therapy (4–6 cycles), patients continuing to receive clinical
benefit defined as ongoing complete response (CR), partial
response (PR), or stable disease (SD) were allowed at the
investigator’s discretion to continue with maintenance single-
agent canfosfamide administered every 3 weeks.
Safety assessments including history, physical exami-
nation, and laboratory evaluations were performed before the
study initiation and at the beginning of each cycle. A com-
plete blood count was obtained at the nadir of each cycle
(between days 8 and 15). Dose modification guidelines for all
three agents were provided in the study protocol and prophy-
lactic growth factor support was allowed per institutional
guidelines. If one or more study drugs were discontinued,
further treatment with the remaining drugs was allowed in the
absence of disease progression. Tumor assessments by com-
puted tomography or magnetic resonance imaging were per-
formed every two cycles. All scans were centrally reviewed
by a blinded, independent reviewer.
Statistical Considerations
Four dose levels of canfosfamide were studied in the
phase 1 dose escalation stage of the study: 400, 500, 750, and
1000 mg/m2. A standard 33 modified Fibonacci design was
employed in which three patients were entered at each can-
fosfamide dose level and if a predefined dose-limiting toxic-
ity (DLT) was observed, the cohort was expanded to six
patients. If no more than none of three (or one of six) patients
treated experienced a DLT, dose escalation proceeded. If 2
DLTs were observed in a cohort, the preceding dose level
would be declared the MTD. A DLT was defined as any
incidence of grade 3 nonhematologic toxicity (with the
exceptions of alopecia, nausea, and vomiting), grade 4
prolonged hematologic toxicity (persisting beyond day 22),
grade 4 febrile neutropenia, or any incidence of thrombo-
cytopenia with bleeding.
The MTD of the combination of canfosfamide with
carboplatin and paclitaxel was identified as 1000 mg/m2, and
the phase 2 study began under an initial plan to enroll up to
35 patients at the MTD in a Fleming 2-stage design with early
stopping at 20 patients if no responses were observed. This
sample size provided 85% power to detect the hypothesis that
the true ORR was at least 20% using a 2.87% (one sided)
false positive error rate if the true ORR were at most 5%. As
a larger cohort of patients was treated at the MTD, a higher
frequency of myelosuppression in later cycles was appreci-
ated in some patients; thus, after 16 patients had enrolled on
the phase 2 stage of the study, a decision was made to reduce
the phase 2 dose of canfosfamide and assess both the 500 and
750 mg/m2 dose levels. The overall accrual goal was also
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expanded to increase the power to select the optimal dose of
the triplet combination for future studies.21 The original
sample size of 35 patients was revised to 100 patients to
obtain at least 35 evaluable patients at each of the new phase
2 dose levels and include the 21 patients already treated at
1000 mg/m2. Patients were enrolled in an alternating fashion
to the 500 and 750 mg/m2 dose levels. Each cohort would
now function as its own Fleming 2-stage study with early
stopping at 20 patients if no responses were observed and an
85% power to observe a true ORR of 20%, as in the initial
design.
Safety, dosing information, and adjunctive treatments
were summarized for all treated patients. Adverse events
were summarized for all patients treated and were graded per
the National Cancer Institute Common Toxicity Criteria (ver-
sion 2.0).22
Efficacy analyses were performed in both the intent-to-
treat and efficacy evaluable population (defined as those who
received at least two cycles of combination therapy). Contin-
uous variables were summarized using descriptive statistics
and categoric variables were summarized by frequencies and
percents. Responses were assessed per RECIST and ORRs
were estimated overall and for each treatment dose level,
along with their exact binomial two-sided 95% confidence
intervals (CIs). The Kaplan-Meier method was used to assess
“time-to-event” variables of OS and PFS. An exploratory
post hoc analysis on all patients eligible for maintenance
therapy, comparing the PFS and OS among those who did
and did not receive maintenance canfosfamide were per-
formed using Cox proportional hazard models, adjusted for
important prognostic factors between the groups (gender,
smoking history, response to combination therapy, and dura-
tion of combination therapy).
RESULTS
Patient Demographics and Treatment
Exposure
One hundred twenty-nine patients were enrolled be-
tween August 2004 and March 2006 from 13 centers in the
US, Table 1. Dose levels of canfosfamide included 400 (n 
3), 500 (n  51), 750 (n  54), and 1000 mg/m2 (n  21).
The disease characteristics of the study population were
consistent with those of patients with newly diagnosed ad-
vanced NSCLC in the US and included 15% with squamous
cell histology, 93% former or current smokers, and 15% with
CNS metastases. A total of 542 cycles of combination treat-
ment were administered, with a median of five cycles per
patient and a range of 1 to 7, Table 2. There was no
significant variation in the median number of cycles of
treatment across the canfosfamide dose levels. One hundred
patients (78%) achieved CR, PR, or SD after triplet combi-
nation therapy and were therefore eligible for maintenance
therapy with canfosfamide alone. Forty-six (46%) of these
patients received a total of 254 cycles of canfosfamide main-
tenance therapy with a median of four cycles (range 1–41).
Efficacy
Efficacy results for the combination regimen are sum-
marized in Table 3. The ORR was 34% (95% CI, 26–44),
including 39 patients with PR and one unconfirmed CR. In
the intent-to-treat analysis, the median survival was 9.9
months (95% CI, 7.7–11.9), and median PFS was 4.3 months
(95% CI, 3.7–5.2).
A post hoc exploratory subgroup analysis was per-
formed comparing the PFS and OS of patients receiving
maintenance canfosfamide therapy (n  46) and of patients









White, non-Hispanic 115 (89)









Squamous cell carcinoma 19 (15)
Other 14 (11)
Large cell carcinoma 11 (9)
Undifferentiated 6 (8)
Mixed (adenocarcinoma and squamous) 5 (4)
Smoking history
Former smoker 94 (73)
Current smoker 26 (20)
Never smoked 9 (7)















a Histologies are not mutually exclusive.
NSCLC, non-small cell lung cancer; ECOG, Eastern Cooperative Oncology Group;
N, number.
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who were eligible to receive maintenance canfosfamide ther-
apy but did not (n  54). Patient therapy designation was at
the discretion of the investigator and was not randomized,
although the two groups seemed well balanced in terms of
age, performance status, smoking history, and histology,
Table 4. Gender and best response to combination therapy
were not balanced between the maintenance and no mainte-
nance groups. Of those eligible for maintenance, 58% of men
and 35% of women were treated, whereas 64% of those with
PR to combination therapy and 36% of those with stable
disease were treated.
Four (17.4%) patients with SD at the start of canfosf-
amide maintenance therapy converted to PR. Both PFS and
OS were prolonged among the patients receiving mainte-
nance canfosfamide compared with the no maintenance pa-
tients, with a median PFS of 6.8 months versus 3.9 months,
respectively (p  0.0001) and median survival of 16.8
months versus 8.8 months, respectively (p  0.0001), Table
4. To estimate the specific contribution of maintenance can-
fosfamide to overall efficacy and adjust for the observed bias
of selecting better responding patients for maintenance, a
proportional hazards model was constructed to analyze time-
to-event variables of PFS and OS from the time of completion
of combination therapy, adjusting for both duration of and
response to combination therapy. The response-adjusted
models yielded a hazard ratio for OS of 0.54 (95% CI
0.31–0.94) and for PFS of 0.32 (95% CI 0.19–0.56), indi-
cating that controlling for response to combination therapy,
canfosfamide maintenance improved outcome compared with
no maintenance therapy.
Adverse Events
All treated patients were included in the safety analysis,
Table 5. The triplet combination regimen of canfosfamide,
carboplatin, and paclitaxel, and the maintenance regimen of
canfosfamide alone were generally well tolerated. Adverse
events assessed by the investigators as possibly related or related
to treatment with the triplet combination were primarily hema-
tologic. Overall, the incidence of hematologic adverse events
was comparable across canfosfamide dose levels in the triplet
TABLE 2. Treatment Administration
Total No. of Cycles Per Patient
in Combination Treatment Phase
400 mg/m2 (N  3) 500 mg/m2 (N  51) 750 mg/m2 (N  54) 1000 mg/m2 (N  21) Total (N  129)
Median 6.0 5.0 4.0 5.0 5.0
Mean 4.7 4.4 3.9 4.3 4.2
Range (2–6) (1–7) (1–6) (1–6) (1–7)
Total No. of Cycles Per Patient
in Maintenance Phase
400 mg/m2 (N  1) 500 mg/m2 (N  19) 750 mg/m2 (N  18) 1000 mg/m2 (N  8) Total (N  46)
Median 4.0 4.0 4.0 2.0 4.0
Mean 4.0 5.4 6.2 4.4 5.5
Range (4–4) (1–41) (1–24) (1–19) (1–41)
N, number.
TABLE 3. Overall Efficacy













N  3 N  45 N  49 N  20 N  117
ORR 2 (67) 18 (40) 13 (27) 7 (35) 40 (34)
PR 2 (67) 18 (40) 13 (27) 7 (35) 40 (34)
SD 0 21 (47) 28 (57) 11 (55) 60 (51)
PD 1 (33) 6 (13) 8 (16) 2 (10) 17 (15)
DSR (PRs  SDs) 2 (67) 39 (87) 41 (84) 18 (90) 100 (86)
Stable disease
3 mo
2 (67) 38 (84) 30 (61) 15 (75) 85 (73)
ITT population N  3 N  51 N  54 N  21 N  129
Median survival,
mo (95% CI)
14.5 (8.7–26.9) 10.3 (6.7–13.0) 7.5 (5.3–12.6) 10.0 (7.7–15.4) 9.9 (7.7–11.9)
Median PFS,
mo (95% CI)
6.8 (1.3–6.9) 5.4 (3.7–5.6) 3.8 (2.8–4.4) 4.9 (3.4–5.9) 4.3 (3.7–5.2)
1-yr survival (%) 66.7 40.3 40.5 42.9 41.3
N, number; CI, confidence interval; PR, partial response; SD, stable disease; PD, progressive disease; DSR, disease stabilization rate; ITT, intent-to-treat; PFS, progression-free
survival.
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combination therapy and canfosfamide maintenance. However,
a higher incidence of grades 3 and 4 thrombocytopenia (52%
and 10%, respectively) and neutropenia (14% and 29%, respec-
tively) was observed in patients treated with canfosfamide at
1000 mg/m2 in combination with carboplatin and paclitaxel than
at lower doses. Febrile neutropenia occurred in three (2%)
patients. Treatment-related grade 3 or 4 adverse events during
canfosfamide maintenance therapy included grade 3 anemia and
grade 4 thrombocytopenia observed in one patient.
Growth factor support for granulocytes was adminis-
tered in 170 (21%) cycles of therapy, for red blood cells in
309 (39%) cycles and for platelets in 22 (3%) cycles, Table 6.
Platelet transfusions were required in 16 (2.1%) cycles, and
red blood cell transfusions were administered in 80 (10%)
cycles. Fifteen patients died within 30 days of receiving
combination therapy of whom 12 were assessed by the
investigators as unrelated to the combination therapy and
because of progressive disease. In three cases, the serious
adverse events ongoing at the time of death were assessed by
the investigator as possibly related or related to the triplet
combination therapy: (1) neutropenic sepsis and typhlitis, (2)
neutropenic sepsis and occipital hemorrhage in a patient with a
history of cerebral vascular accidents and a platelet count of
75,000, and (3) cholestatic jaundice in a patient with intrahepatic
and extrahepatic bile duct dilatation from tumor involvement.
DISCUSSION
We have demonstrated that the combination regimen of
canfosfamide, carboplatin, and paclitaxel as first-line therapy
for advanced NSCLC is active and well tolerated. In a
multicenter phase 2 setting, an ORR of 34% with median PFS
of 4.3 months and median survival of 9.9 months were
observed. Objective responses occurred at all canfosfamide
dose levels tested, in all histologic subtypes of NSCLC, in
patients with CNS metastases and regardless of smoking
status. Furthermore, maintenance therapy with single agent
canfosfamide in patients continuing to receive clinical benefit
at the completion of combination chemotherapy was well
tolerated and may be associated with further prolongation of
PFS and OS. This study is one of the first examples high-
lighting the potential utility of targeting the GST P1–1 path-
way in NSCLC therapy.
TABLE 4. Patients Eligible for Canfosfamide Maintenance Therapy
Demographics and NSCLC Disease Characteristics
Patient Characteristic
Maintenance Therapy,
N  46, n (%)
No Maintenance Therapy,
N  54, n (%)
Percent of Patients of Each Characteristic
Receiving Maintenance Therapy (%)
Age, median (range) 62 (42–80) 62 (31–78)
Gender
Male 28 (61) 20 (37) 58
Female 18 (39) 34 (63) 35
ECOG
0 22 (48) 23 (43) 49
1 24 (52) 31 (57) 44
Histology
Adenocarcinoma 26 (57) 32 (59) 45
Squamous cell carcinoma 7 (15) 6 (11) 54
Large cell carcinoma 4 (9) 5 (9) 44
Smoking history
Former smoker 32 (70) 40 (74) 44
Current smoker 10 (22) 10 (19) 50
Never smoked 4 (9) 4 (7) 50
Status at end of combination chemotherapy
Partial response 23 (50) 13 (24) 64
Stable disease 23 (50) 41 (76) 36
Efficacy
Maintenance Therapy,
N  46, n (%)
No Maintenance Therapy,
N  54, n (%) p
Hazard Ratio
(95% CI)
Median overall survival, mo (95% CI)a 16.8 (12.8–22.6) 8.8 (6.4–12.1) 0.0001 0.38 (0.24–0.62)
Median PFS, mo (95% CI)a 6.8 (6.1–7.2) 3.9 (3.4–4.3) 0.0001 0.21 (0.13–0.35)
Median overall survival (response-adjusted, from
end of combination chemotherapy), mo (95% CI)b
12.4 (8.5–17.6) 4.7 (2.8–8.2) 0.0291 0.54 (0.31–0.94)
Median PFS (response-adjusted, from end of
combination chemotherapy), mo (95% CI)b
2.6 (1.9–2.8) 0.7 (0.5–1.2) 0.0001 0.33 (0.19–0.56)
NSCLC, non-small cell lung cancer; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; PFS, progression-free survival; N, number.
a Cox model adjusted for gender, current smoker vs other.
b Cox model adjusted for gender, current smoker vs other, response status at end of combination chemotherapy, and duration of combination chemotherapy.
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Several novel agents have been investigated in triplet
combinations with platinum-based doublets as first-line ther-
apy for advanced NSCLC. In the majority of these studies,
despite promising phase 2 results, randomized phase 3 trials
comparing chemotherapy with and without the novel agent
have failed to demonstrate a survival advantage.23–31 The
only novel agents that have shown a survival benefit when
added to platinum-based therapy thus far have been mono-
clonal antibodies (mAb), specifically bevacizumab, a mAb
against vascular endothelial growth factor, and cetuximab, a
mAb against epidermal growth factor receptor.4,32 In the
landmark E4599 study, adding bevacizumab to carboplatin
and paclitaxel chemotherapy improved median OS from 10.3
to 12.3 months (p  0.001).4 However, it is notable that
because of the side effect profile of bevacizumab this trial
was performed in a select group of patients with relatively
good prognoses compared with average NSCLC patients,
namely those with nonsquamous NSCLC and absence of
CNS metastases. The FLEX trial similarly demonstrated an
improvement in median OS from 10.1 to 11.3 months (p 
0.044) when cetuximab was added to cisplatin and vinorel-
bine chemotherapy.32 Here, patients were selected based on
expression of epidermal growth factor receptor by immuno-
histochemical analysis of a biopsy specimen. The ability to
select patients either less likely to have toxicity from the
experimental regimen or more likely to respond to the exper-
TABLE 5. Treatment-Related Hematologic and Nonhematologic Adverse Events
Canfosfamide  Carboplatin  Paclitaxel Combination Therapy
400 mg/m2 (N  3) 500 mg/m2 (N  51) 750 mg/m2 (N  54)
1000 mg/m2






















Anemia 0 0 6 (12) 5 (9) 1 (2) 4 (19) 0 15 (12) 1 (1)
Febrile neutropenia 0 0 0 0 2 (4) 0 1 (5) 0 3 (2) 0
Leukopenia 0 0 8 (16) 2 (4) 8 (15) 2 (4) 4 (19) 0 20 (16) 4 (3)
Neutropenia 0 1 (33) 4 (8) 11 (22) 6 (11) 19 (35) 3 (14) 6 (29) 13 (10) 37 (29)
Pancytopenia 0 0 2 (4) 0 0 3 (6) 0 0 2 (2) 3 (2)
Thrombocytopenia 1 (33) 0 11 (22) 1 (2) 18 (33) 5 (9) 11 (52) 2 (10) 41 (32) 9 (6)
Nonhematologic
Fatigue 0 0 7 (14) 0 4 (7) 1 (2) 2 (10) 0 13 (10) 1 (1)
Nausea 0 0 3 (6) 0 1 (2) 0 2 (10) 0 6 (5) 0
Vomiting 0 0 4 (8) 0 1 (2) 0 0 0 5 (4) 0
Neuropathy (sensory) 0 0 1 (2) 0 1 (2) 0 1 (5) 0 2 (2) 0
Neuropathy (peripheral) 0 0 3 (6) 0 1 (2) 0 0 0 4 (3) 0










Anemia 4 (9) 1 (2) 1 (2) 0
Leukopenia 4 (9) 1 (2) 0 0
Neutropenia 4 (9) 1 (2) 0 0
Thrombocytopenia 8 (17) 1 (2) 0 1 (2)
Nonhematologic
Fatigue 1 (2) 7 (15) 0 0
Nausea 5 (11) 2 (4) 0 0
Vomiting 3 (6) 1 (2) 1 (2) 0
Diarrhea 2 (2) 0 1 (2) 0
N, number.















Erythropoietin support 40/43 309 (39)
RBC transfusions 13/0 80 (10)
Platelet transfusions 3/0 16 (2)
Platelet growth factor 3/0 22 (3)
RBC, red blood cell; N, number.
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imental regimen is certainly an advantage in designing a
randomized trial, and studies are ongoing to identify such a
population with regards to canfosfamide. The results from
our phase 2 study are on par with those observed in phase 2
studies of bevacizumab and cetuximab in combination with
chemotherapy; we had an ORR of 34%, median PFS of 4.9
months, and median OS of 9.6 months, the bevacizumab
phase 2 study had an ORR of 31%, median PFS of 7.4
months, and median OS of 17.7 months, and the cetuximab
phase 2 study had an ORR of 35%, median PFS of 5.0
months, and median OS of 8.3 months.33,34
As is typically seen when adding an additional agent to
a combination regimen, the canfosfamide-containing triplet
had increased myelosuppression compared with historical
results with carboplatin and paclitaxel. This was initially
noted at an interim safety analysis performed after 16 patients
had enrolled in the phase 2 stage of the study at the MTD,
1000 mg/m2 of canfosfamide. Grades 3 to 4 neutropenia was
seen in 33% of these patients and grades 3 to 4 thrombocy-
topenia in 38%, rates two to fivefold higher than with carbo-
platin and paclitaxel.2,4,24,26 After the subsequent protocol
amendment which decreased the doses of canfosfamide to
500 and 750 mg/m2, the rates of myelosuppression were
considerably reduced, Table 5. Given that activity was ap-
proximately equal at all doses tested, the optimal dose of
canfosfamide to be used in further studies in combination
with carboplatin and paclitaxel is 750 mg/m2, the highest
dose tested yielding a reasonable safety profile.
Finally, a provocative exploratory analysis of our study
suggested that among patients who had not progressed during
combination therapy, the addition of maintenance canfosf-
amide may be beneficial, with a prolongation in both PFS and
OS observed in this group. Although it should be noted that
this analysis was not prespecified, models adjusting for im-
portant prognostic factors as well as response to combination
chemotherapy were constructed to improve precision in as-
sessing the effect of canfosfamide maintenance therapy in
this nonrandomized setting, and to reduce the impact of
selection bias. Of the prognostic factors that were imbal-
anced, the discrepancy in response status favored the main-
tenance arm with a larger proportion of patients achieving PR
opting for further therapy; whereas the disparity in gender
favored the no maintenance arm, with fewer women (a good
prognostic factor in NSCLC) receiving maintenance. The
improvements in OS and PFS observed during maintenance
therapy were clinically relevant (7.7 and 1.9 months, respec-
tively) and hence maintenance canfosfamide after triplet
combination therapy should be prospectively studied. Al-
though maintenance therapy has not traditionally been a
widely used strategy in NSCLC treatment algorithms, this
concept is gaining increased acceptance and validity as seven
large randomized studies have recently had positive results
incorporating a maintenance approach. Both the E4599 study
and the FLEX study continued their targeted agent (bevaci-
zumab or cetuximab) as maintenance after chemotherapy was
completed.4,32 Now, five additional randomized studies have
demonstrated an improvement in PFS (and OS in one study)
with early initiation of second-line noncross-resistant main-
tenance therapy (with docetaxel, pemetrexed, erlotinib, or
gefitinib) after platinum-based combination chemotherapy,
rather than waiting for clinical disease progression.35–39 As a
result of this literature, maintenance therapy is an emerging
trend in NSCLC clinical trial design, and the results of our
study suggest canfosfamide should also be further studied
with this strategy.
In conclusion, the combination of canfosfamide, a
novel glutathione prodrug, with standard carboplatin and
paclitaxel chemotherapy is feasible, well tolerated, and ac-
tive. Maintenance canfosfamide therapy may further improve
outcomes. This regimen is worthy of additional study and
ongoing investigations are attempting to identify the charac-
teristics of the NSCLC population most likely to benefit from
therapy.
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